Minaris to be commercial manufacturer in Europe for Skysona, bluebird bio’s gene therapy for CALD
Minaris Regenerative Medicine, a leading contract development and manufacturing organization for the cell and gene therapy industry, will be the commercial manufacturer in Europe for bluebird bio’s Skysona (elivaldogene autotemcel, formerly Lenti-D gene therapy), for the treatment of Early Cerebral Adrenoleukodystrophy (CALD).